According to information released by Dongcheng Pharmaceutical, the US Food and Drug Administration (FDA) recently granted APN-1607 Fast Track accreditation. Fast track eligibility is a policy set by the FDA to expedite approval of clinically needed products.
东诚药业：APN-1607获得美国FDA快速通道资格认定
Dongcheng Pharmaceutical: APN-1607 obtained US FDA Fast Track Qualification
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.